Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
- 1 August 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 362 (9384) , 617-619
- https://doi.org/10.1016/s0140-6736(03)14182-7
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic responseThe Lancet, 1995